Dermira, Inc. (NASDAQ:DERM) – Equities researchers at Leerink Swann decreased their Q3 2017 earnings per share estimates for shares of Dermira in a report released on Monday. Leerink Swann analyst S. Fernandez now forecasts that the biopharmaceutical company will post earnings of ($1.03) per share for the quarter, down from their previous forecast of ($1.00). Leerink Swann also issued estimates for Dermira’s Q4 2017 earnings at ($1.29) EPS, FY2017 earnings at ($4.06) EPS, FY2018 earnings at ($2.24) EPS and FY2019 earnings at $0.38 EPS.
Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by $0.04. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. TRADEMARK VIOLATION NOTICE: This article was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://sportsperspectives.com/2017/08/10/leerink-swann-comments-on-dermira-inc-s-q3-2017-earnings-nasdaqderm.html.
A number of other analysts have also issued reports on the company. BidaskClub lowered Dermira from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 target price on shares of Dermira in a research report on Tuesday, July 18th. Evercore ISI began coverage on Dermira in a research report on Thursday, June 29th. They set an “outperform” rating and a $48.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Dermira in a research report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 target price on the stock. Five research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $43.80.
Dermira (DERM) opened at 22.56 on Thursday. The stock’s 50 day moving average price is $28.50 and its 200 day moving average price is $30.77. The firm’s market capitalization is $936.71 million. Dermira has a 52-week low of $21.35 and a 52-week high of $38.75.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Dermira by 4,816.7% in the first quarter. BlackRock Inc. now owns 3,392,848 shares of the biopharmaceutical company’s stock valued at $115,729,000 after buying an additional 3,323,841 shares during the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in shares of Dermira during the first quarter valued at approximately $20,296,000. Marshall Wace North America L.P. purchased a new stake in shares of Dermira during the first quarter valued at approximately $20,296,000. Jana Partners LLC boosted its stake in shares of Dermira by 171.0% in the first quarter. Jana Partners LLC now owns 655,252 shares of the biopharmaceutical company’s stock valued at $22,351,000 after buying an additional 413,442 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Dermira by 16.7% in the second quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock valued at $76,725,000 after buying an additional 377,554 shares during the last quarter. Institutional investors and hedge funds own 84.57% of the company’s stock.
In other news, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Christopher M. Griffith sold 1,312 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $27.07, for a total value of $35,515.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,812 shares of company stock valued at $482,231. Insiders own 13.30% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.